Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Hsu CL, Liu JS, Wu PL, Guan HH, Chen YL, Lin AC, Ting HJ, Pang ST, Yeh SD, Ma WL, Chen CJ, Wu WG, Chang C.

Mol Oncol. 2014 Dec;8(8):1575-87. doi: 10.1016/j.molonc.2014.06.009. Epub 2014 Jun 24.

2.

Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.

Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM.

J Biol Chem. 2007 Aug 31;282(35):25801-16. Epub 2007 Jun 25.

3.

Structural features discriminate androgen receptor N/C terminal and coactivator interactions.

Askew EB, Minges JT, Hnat AT, Wilson EM.

Mol Cell Endocrinol. 2012 Jan 30;348(2):403-10. doi: 10.1016/j.mce.2011.03.026. Epub 2011 Jun 1. Review.

4.

Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth.

Hsu CL, Chen YL, Ting HJ, Lin WJ, Yang Z, Zhang Y, Wang L, Wu CT, Chang HC, Yeh S, Pimplikar SW, Chang C.

Mol Endocrinol. 2005 Feb;19(2):350-61. Epub 2004 Oct 28.

PMID:
15514032
5.

Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.

Jääskeläinen J, Deeb A, Schwabe JW, Mongan NP, Martin H, Hughes IA.

J Mol Endocrinol. 2006 Apr;36(2):361-8.

PMID:
16595706
6.

Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.

Dubbink HJ, Hersmus R, Pike AC, Molier M, Brinkmann AO, Jenster G, Trapman J.

Mol Endocrinol. 2006 Aug;20(8):1742-55. Epub 2006 Apr 20.

PMID:
16627595
7.

The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.

Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS.

Biochemistry. 2007 Jan 23;46(3):683-95.

PMID:
17223690
8.

Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells.

Buchanan G, Need EF, Barrett JM, Bianco-Miotto T, Thompson VC, Butler LM, Marshall VR, Tilley WD, Coetzee GA.

Mol Cell Endocrinol. 2011 Aug 6;342(1-2):20-31. doi: 10.1016/j.mce.2011.05.023. Epub 2011 Jun 1.

9.

Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.

Xu D, Lin TH, Li S, Da J, Wen XQ, Ding J, Chang C, Yeh S.

Cancer Lett. 2012 Mar;316(1):11-22. doi: 10.1016/j.canlet.2011.10.006. Epub 2011 Oct 10.

10.

The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.

Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z.

Am J Pathol. 2003 Jan;162(1):233-41.

11.

Recognition and accommodation at the androgen receptor coactivator binding interface.

Hur E, Pfaff SJ, Payne ES, Grøn H, Buehrer BM, Fletterick RJ.

PLoS Biol. 2004 Sep;2(9):E274. Epub 2004 Aug 24.

12.

The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs.

Hsu CL, Chen YL, Yeh S, Ting HJ, Hu YC, Lin H, Wang X, Chang C.

J Biol Chem. 2003 Jun 27;278(26):23691-8. Epub 2003 Apr 24.

13.

Minoxidil may suppress androgen receptor-related functions.

Hsu CL, Liu JS, Lin AC, Yang CH, Chung WH, Wu WG.

Oncotarget. 2014 Apr 30;5(8):2187-97.

14.

Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.

Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.

Cancer Res. 2009 Oct 15;69(20):8141-9. doi: 10.1158/0008-5472.CAN-09-0919. Epub 2009 Oct 6.

15.

The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.

Chen ST, Okada M, Nakato R, Izumi K, Bando M, Shirahige K.

J Biol Chem. 2015 Aug 28;290(35):21713-23. doi: 10.1074/jbc.M114.628255. Epub 2015 Jul 14.

16.

Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.

Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP.

Clin Cancer Res. 2014 Aug 1;20(15):4075-85. doi: 10.1158/1078-0432.CCR-14-0292. Epub 2014 May 29.

17.

Influence of short polyglutamine tracts and p160 coactivators on the transactivation of the androgen receptor.

Shi XB, Xue L, Shi D, deVere White RW.

Cancer Biother Radiopharm. 2011 Apr;26(2):191-201. doi: 10.1089/cbr.2010.0888.

18.

A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth.

Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, Nishimura K, Fujimoto N, Chang C.

J Biol Chem. 2002 Feb 15;277(7):4609-17. Epub 2001 Oct 22.

19.

Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.

D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, Koochekpour S, Isaacs JT.

PLoS One. 2010 Jul 8;5(7):e11475. doi: 10.1371/journal.pone.0011475.

20.

Allosteric conversation in the androgen receptor ligand-binding domain surfaces.

Grosdidier S, Carbó LR, Buzón V, Brooke G, Nguyen P, Baxter JD, Bevan C, Webb P, Estébanez-Perpiñá E, Fernández-Recio J.

Mol Endocrinol. 2012 Jul;26(7):1078-90. doi: 10.1210/me.2011-1281. Epub 2012 May 31.

Supplemental Content

Support Center